Dr. Rovner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414Fax+1 843-792-9252
Summary
- Eric S. Rovner, M.D. is a Professor in the Department of Urology at the Medical University of South Carolina (MUSC) in Charleston, South Carolina. He is the director of the Section of Voiding Dysfunction, Female Urology and Urodynamics in the Department of Urology at MUSC. He has a highly specialized clinical practice within Urology and sees mostly patients with complex voiding problems including urinary incontinence, vaginal prolapse, urinary fistulae and neurogenic bladder dysfunction.
He is a Board Certified member of the American Urological Association, Fellow of the American College of Surgeons, as well as a member of the Society of Pelvic Surgeons, Society of University Urologists, Societe Internationale D’Urologie, and the Society for Urodynamics and Female Urology (SUFU) among others. He is the President of SUFU. Dr. Rovner has served on several committees for the WHO International Consultation on Incontinence and has been a member of the AUA Urodynamics Guidelines Committee, and SUI Guidelines Committee. He has served on the AUA/ABU Exam Committee as well as the ABU Oral Exam Committee.
Dr. Rovner’s research interests include the study of voiding dysfunction, overactive bladder, interstitial cystitis, neurourology and urodynamics. He has held several visiting professorships and is the author of numerous peer-reviewed scientific articles, monographs and book chapters on these topics as well as a book on urinary incontinence. He has been an invited speaker on numerous occasions throughout the United States and the world, and has been the Principal or co-investigator on multiple grants.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Female Pelvic Medicine And Reconstructive Surgery (Urology), 1996 - 1999
- University of Pennsylvania Health SystemResidency, Urology, 1992 - 1996
- University of Pennsylvania Health SystemInternship, Surgery, 1991 - 1992
- Albert Einstein College of MedicineClass of 1991
Certifications & Licensure
- CA State Medical License 1996 - 2025
- SC State Medical License 2004 - 2025
- PA State Medical License 1993 - 2006
- NJ State Medical License 2002 - 2005
- American Board of Urology Urology
- American Board of Urology Female Pelvic Medicine and Reconstructive Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Solace Stress Urinary inContinence Control Efficacy and Safety Study Start of enrollment: 2014 Aug 11
- Prospective US Radiofrequency SUI Trial Start of enrollment: 2021 Jan 11
Publications & Presentations
PubMed
- The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder.Anne P Cameron, Doreen E Chung, Elodi J Dielubanza, Ekene Enemchukwu, David A Ginsberg
Neurourology and Urodynamics. 2024-11-01 - Towards a minimum data set for the female stress urinary incontinence surgical literature: a collaborative work.Eric S Rovner
Current Opinion in Urology. 2024-11-01 - 2 citationsRecommendations of the SUFU/AUGS/ICS Female Stress Urinary Incontinence Surgical Publication Working Group: A common standard minimum data set for the literature.Eric Rovner, Christopher Chermansky, Elisabetta Costantini, Roger Dmochowski, Ekene Enemchukwu
Neurourology and Urodynamics. 2024-11-01
Journal Articles
- Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of TreatmentAlfred Kohan, Eric Rovner, Victor Nitti, The Journal of Urology
- Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of TreatmentEric Rovner, Victor Nitti, Alfred Kohan, The Journal of Urology
Press Mentions
- Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive BladderFebruary 25th, 2020
- Solace Therapeutics Says 3rd Trial of Vesair Bladder Device Met EndpointsMarch 1st, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: